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ABBREVIATIONS 
BHB, ² -hydroxybutyrate; ECL, extracellular loop, fMLP, N-formylmethionyl-leucyl-
phenylalanine; GPCR, G protein-coupled receptor; GSIS, glucose-stimulated insulin 
secretion; HDAC, histone deacetylase; HTS, high throughput screen, LE, ligand 
efficiency; NAM, negative allosteric modular; PAM, positive allosteric modulator; 
PBMC, peripheral blood mononuclear cell; PMN, polymorphic nucleocyte; PTX, 
pertussis toxin; ROS, reactive oxygen species; SAR, structure activity relationship, SCA, 
small, non-fatty acid, carboxylic acids; SCFA, short chain fatty acids; TM 
transmembrane; TPN, total parenteral nutrition 
 
Chemical Names 
4-CMTB, [(S)-2-(4-chlorophenyl)-3- methyl-N-(thiazol-2-yl)butanamide]; CATPB, (S)-
3-(2-(3-chlorophenyl)acetamido)-4-(4-(trifluoromethyl)phenyl)butanoic acid; compound 
1, 3-benzyl-4-(cyclopropyl-(4-(2,5-dichlorophenyl)thiazol-2-yl)amino)-4-oxobutanoic  
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acid; GLPG0974, -[[(R)-1-(benzo[b]thiophene-3-carbonyl)-2-methyl-azetidine-2-
carbonyl]-(3-chloro-benzyl)-amino]-butyric acid; AR420626, N-(2,5-dichlorophenyl)-4-
(furan-2-yl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide; compound 
6, 2-methyl-5-oxo-4-(3-phenoxyphenyl)-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-
carboxamide; sorbic acid, 2,4-hexadienoic acid.  
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ABSTRACT 
Despite some block-buster G protein-coupled receptor (GPCR) drugs only a small 
fraction (~15%) of the more than 390 non-odorant GPCRs have been successfully 
targeted by the pharmaceutical industry. One way that this issue might be addressed is via 
translation of recent de-ophanization programmes that have opened the prospect of 
extending the reach of new medicine design to novel receptor types with potential 
therapeutic value. Prominent among these receptors are those that respond to short chain 
free fatty acids of carbon chain length 2-6. These receptors, FFA2 (GPR43) and FFA3 
(GPR41), are each activated by the predominant short chin fatty acids acetate, propionate 
and butyrate, ligands that originate largely as fermentation by-products of anaerobic 
bacteria in the gut. However, the presence of FFA2 and FFA3 on pancreatic ² -cells, 
FFA3 on neurons and FFA2 on leukocytes and adipocytes means that the biological role 
of these receptors likely extends beyond that of the widely accepted role of regulating 
peptide hormone release from enteroendocrine cells in the gut. Here we review the 
physiological roles of FFA2 and FFA3, the recent development and use of receptor 
selective pharmacological tool compounds and genetic models available to study these 
receptors and present evidence of the potential therapeutic value of targeting this 
emerging receptor pair.  
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INTRODUCTION 
Short Chain Fatty Acids (SCFAs) are saturated aliphatic organic acids containing 2 to 6 
carbon atoms. Within the body they are predominantly the by-product of the fermentation 
of non-digestible carbohydrates (fibers) through the action of intestinal anaerobic bacteria 
(den Besten et al., 2013). The amount of SCFAs released in the intestine is influenced by 
several factors, among which are the strain and quantity of microbiota in the colon, 
substrate source and intestinal transit time (Wong et al., 2006). In general, SCFAs reach 
an intestinal concentration in the millimolar region, in which acetate (C2), propionate 
(C3) and butyrate (C4) represent the most abundant metabolite species (e95%) (Topping 
and Clifton, 2001). In 2003, the previously orphan seven transmembrane (TM) domain 
polypeptides GPR41 and GPR43 were identified as G protein-coupled receptors (GPCRs) 
that are activated by SCFAs (Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 
2003). Following this discovery, interest surrounding SCFAs and their receptors has risen 
dramatically, both in relation to the discovery of selective ligands and the physiological 
role of these receptors. GPR41 and GPR43 were subsequently renamed FFA3 and FFA2, 
respectively (Stoddart et al., 2008a) based on their responsiveness to SCFAs. 
 
FFA2/FFA3 receptor structure and signal transduction 
The genes encoding FFA2 and FFA3, together with the medium/long chain fatty acid 
receptor GPR40 (FFA1, Stoddart et al., 2008a), cluster as a group of intronless sequences 
located in human at chromosome 19q13.1. They were first identified during a search for 
novel human galanin receptor subtypes (Sawzdargo et al., 1997). A further gene that 
shares 98% identity with FFA3, was also identified within this region, and is designated 
GPR42. This latter potential receptor is now classified as a functional polymorph of 
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FFA3, although its physiological role and expression in humans is yet to be fully clarified 
(Liaw and Connolly, 2009; Puhl et al., 2015). FFA2 and FFA3 are closely related, with 
43% amino acid identity (Stoddart et al., 2008a). This translates into poor ligand 
selectivity between the two receptors. Nonetheless, there is a rank order of potency for 
SCFAs in activating human FFA2 and FFA3 receptors, where FFA2 is activated more 
potently by shorter chain fatty acids whilst, in general, the opposite is the case for FFA3. 
Specifically, the rank order of potency for human FFA2 is reported as 
C2=C3>C4>C5=C1, whereas at human FFA3 it is C3=C4=C5>C2>C1 (Milligan et al., 
2009) (Figure 1).  Although this results in acetate being significantly more potent at 
human FFA2 than at human FFA3 (Schmidt et al., 2011) and is sometimes, therefore, 
employed as a selective activator of FFA2, there is great need to identify more selective 
synthetic ligands that would allow improved discrimination between the biological 
functions of FFA2 versus FFA3 both in vitro and in vivo.  
 The de-orphanization of GPR41 and GPR43 led to the observation that the 
carboxylic acid group of SCFAs is the key element in the activity of these endogenous 
molecules at both receptors. Previous studies had shown that positively charged amino 
acids within the TM regions are essential for the binding and function of other GPCRs 
whose ligands contain a carboxylic acid group (Stitham et al., 2003; He et al., 2004; 
Tunaru et al., 2005; Sabirsh et al., 2006). This, together with the observation that 
uncharged ester derivatives of SCFAs are inactive at FFA2 and FFA3 (Le Poul et al., 
2003), led Milligan’s group to hypothesize that basic residues might also play a crucial 
role in the binding of SCFAs to their receptors (Stoddart et al., 2008b). Sequence 
alignment of FFA2 and FFA3 with FFA1 revealed that five positively charged amino 
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acids were conserved across these fatty acid receptors. Generation of homology models, 
linked to a mutagenic strategy, was then employed to identify the key polar amino acids 
for ligand recognition contained in the water-filled cavity within the TM domains of 
FFA2 and FFA3 (Stoddart et al., 2008b). From this, four positively charged amino acid 
residues were identified: Histidine (His) in TM IV (residue position 4.56); Arginine (Arg) 
in TM V (5.39); His in TM VI (6.55); Arg in TM VII (7.35) (Stoddart et al., 2008b) (for a 
more detailed consideration of the position and significance of these amino acids in FFA2 
and FFA3 see Ulven, 2012). Studies in cells expressing alanine-substituted forms of these 
residues in FFA2 and FFA3 led to the conclusion that both Arg 5.39 and 7.35, as well as 
His 6.55, were essential for co-ordinating the recognition and functionality of SCFAs at 
both FFA2 and FFA3. Indeed, in each case, these alterations completely abrogated 
response to SCFAs (Stoddart et al., 2008b). By contrast, mutation of His 4.56 displayed a 
more diverse outcome between the two receptors, suggesting that this amino acid may not 
be directly involved in the binding of the carboxylate group but, rather, plays a role in 
fatty acid chain length selectivity (Stoddart et al., 2008b). The identification of these key 
residues involved in the orthosteric binding site paved the way for the study of other, and 
potentially selective, small molecule ligands. Schimdt and colleagues established 
structure-activity relationships (SAR) of a group of small, non-fatty acid, carboxylic 
acids (SCAs) at FFA2 (Schimdt et al., 2011). Although this work identified some 
molecules that were relatively selective for FFA2 over FFA3, for example 2,2-
dimethylacrylic acid has approximately 800 times higher potency at FFA2 compared to 
FFA3, the potency of such molecules was still very modest and too low to be useful as 
pharmacological tools for in vitro and, particularly, in vivo studies. Given the small size 
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of these molecules, the low potency of both SCFAs and SCAs is hardly surprising. 
However, they did display high ligand efficiency (LE). LE is a measure of ligand binding 
free energy per heavy atom count and is mathematically expressed by delta g (Hopkins et 
al., 2014). This concept has been widely used for the selection and optimization of 
fragments or small ligands at specific pharmacological targets. Schmidt et al. (2011) 
indicated that the ligand efficiency for C2, C3 and SCAs was approaching the maximal 
possible delta g value, indicating that it would be unlikely that potency at FFA2 and 
FFA3 could be improved without increasing ligand size substantially.   
 An additional binding pocket in FFA2, distinct from that for the endogenously 
produced SCFAs, was first hypothesized by researchers at Amgen. This was based on 
outcomes from a high throughput screen (HTS) campaign to identify FFA2 activators 
(Lee et al., 2008). This resulted in the characterization of the first moderately potent 
FFA2 selective, synthetic ligand, [(S)-2-(4-chlorophenyl)-3- methyl-N-(thiazol-2-
yl)butanamide] (4-CMTB) (Figure 1). This ligand was shown to cause activation of both 
G±i/o and G±q/11-mediated pathways via FFA2 with no effect at FFA3 (Lee et al., 2008). 
Despite this, some subsequent studies have indicated very limited ability of this ligand to 
produce elevation of Ca2+ levels in transfected cells (see later).  Moreover, further 
analyses of the pharmacological properties of this ligand revealed an ability to exert 
positive cooperativity with both C3 and C2, indicating that 4-CMTB behaves as an 
allosteric agonist at FFA2 (Lee et al., 2008; Wang et al., 2010; Smith et al., 2011).  
Mutagenic studies have revealed that extracellular loop 2 (ECL2) plays an important role 
in the allosteric effect of 4-CMTB. Replacement of ECL2 in FFA2 with the equivalent 
region from FFA3 completely abolished the observed positive cooperativity between 4-
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CMTB and C3 (Smith et al., 2011). Despite this, the details of the ‘allosteric’ binding 
pocket for 4-CMTB remain to be fully defined.   
As noted earlier, in terms of signal transduction FFA2 is a promiscuous receptor 
that has the ability to couple to pathways transduced by both G±i/o and G±q/11 proteins 
(Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003). Moreover, screens 
performed in strains of the yeast S. cerevisiae containing different yeast/mammalian G± 
subunit chimeras, also indicated an ability of FFA2 to interact with G±12, G±13 and G±14 
(Brown et al., 2003). However, interaction of FFA2 with these G proteins has yet to be 
validated in cells that express native, full length mammalian G proteins.  By contrast, the 
activation of FFA3 appears to induce only G±i/o-mediated signaling as receptor effects are 
generally attenuated by pertussis toxin (PTX) treatment of cells (Brown et al., 2003; Le 
Poul et al., 2003). In addition, SCFA occupancy of FFA2 has been reported to recruit 
both ² -arrestin-1 and, in particular, ² -arrestin-2 to the receptor and these are responsible 
for FFA2 internalization from the cell surface and the initiation of G protein-independent 
signal transduction (Hudson et al., 2012b and 2013b; Lee et al., 2013). To date there are 
no published data regarding the ability of FFA3 to recruit arrestin isoforms.  
 
Physiological roles of FFA2/FFA3 
Roles in immune cells 
When the tissue expression of FFA2 was first described, its most notable presence 
was in cells of the innate immune system, both polymorphic nucleocytes (PMNs) and 
peripheral blood mononuclear cells (PBMCs) (Le Poul et al., 2003)  (Figure 2). Recent 
studies have confirmed presence of FFA2 in neutrophils, eosinophils (Maslowski et al., 
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2009), and in leukocytes of the lamina propia (Nøhr et al., 2013). The presence of FFA3 
remains contentious (Brown et al., 2003; Maslowski et al., 2009). Naturally, given that 
SCFAs are a by-product of anaerobic fermentation by gut bacteria, it is to be expected 
that immune cells should be able to respond to such ligands.  
One area of particular interest is inflammatory conditions of the lower gut, such as 
ulcerative colitis and Crohn’s disease (Xavier and Podolsky, 2007). Butyrate enemas 
have been used to attempt to treat colitis, with mixed results (Bocker et al., 2003), and a 
high fiber diet can result in improvement in ulcer and colitis scores, with matching 
reduction in neutrophil infiltration (Kataoka et al., 2008). Despite these promising results, 
two different studies examining the role of FFA2 in rodent models of colitis have 
generated conflicting effects. Maslowski et al. (2009) found that colitis could be rescued 
in germ-free mice by FFA2 agonism with acetate, whereas Sina et al. (2009) found that 
SCFA recruit PMNs via FFA2 to worsen tissue damage. Moreover, a`first in man` 
clinical trial with the FFA2 antagonist, GLPG0974 (see later), for the treatment of 
ulcerative colitis did not provide any immediate beneficial effects, resulting in this study 
being terminated. Clearly, FFA2 signaling in leukocytes is a complicated scenario, which 
deserves further dissection and analysis.  
Most reports suggest that SCFAs mediate a shift from pro-inflammatory to anti-
inflammatory cytokine release from leukocytes. C2 and C4 can inhibit TNF-± release 
(Säemann et al., 2000; Maslowski et al., 2009; Ohira et al., 2013), and C4 in particular 
can mediate a switch from a Th1 (which is exaggerated in Crohn’s disease) to a Th2 
profile of cytokine production (Säemann et al., 2000; Cavaglieri et al., 2003). Both FFA2 
and FFA3 knock-out mice do not recruit Th1 cells in a rectal inflammation model (Kim 
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et al., 2013). Finally, C3 can trigger the release of the anti-inflammatory IL-10 from 
regulatory T cells, and this happens in a FFA2-specific manner (Smith et al., 2013). 
In terms of cell signaling, C2 and C3 (Le Poul et al., 2003; Maslowski et al., 
2009) but not C4 (Nakao et al., 1992) increase intracellular Ca2+ in PMNs, in a manner 
that has been described as partially (Nakao et al., 1992) or fully PTX insensitive, and 
intracellular store-dependent (Le Poul et al., 2003), raising the possibility that this effect 
may be mediated via FFA2 and G±q/11. PMNs require calcium for chemotaxis towards N-
formylmethionyl-leucyl-phenylalanine (fMLP), a peptide which is often used as a model 
of bacteria-stimulated chemotaxis (Chen and Jan, 2001). PMNs migrate along a C3 or C4 
gradient, in a FFA2, p38, ERK1/2, and pAkt specific manner; and this appears to be 
PTX-sensitive, implicating G±i/o, in addition to G±q/11 (Sina et al., 2009; Vinolo et al., 
2011).  Neutrophils use reactive oxygen species (ROS) in phagosomes to kill internalized 
bacteria (Nordenfelt and Tapper, 2011), but ROS also play a role as signaling molecules 
involved in chemotaxis (Hattori et al., 2010).  C4 inhibits ROS production in neutrophils 
stimulated with fMLP via cAMP, and a PTX-sensitive release of G protein G² ³  complex. 
Conversely, C2 increases ROS production in a PTX-insensitive manner (Vinolo et al., 
2009), and macrophages lacking FFA2 do not produce ROS in a model of gouty arthritis 
(Vieira et al., 2015). Potentially this may reflect opposing signaling via FFA2 and G±q/11 
and FFA3 and G±i/o. ROS also contribute to apoptosis in neutrophils - a process which 
helps limit the extent of inflammation (Nordenfelt and Tapper, 2011) – and C2 increases 
apoptosis (Maslowski et al., 2009), perhaps again via FFA2.  
Broadly speaking, it would appear that C2 and C3 stimulate, whilst C4 inhibits, the 
various functions of innate immune cells. This may explain conflicting results using 
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mixes of SCFAs, although non-receptor mediated effects cannot be ruled out. In terms of 
cytokine release, all SCFAs appear to have anti-inflammatory effects. There are not yet 
many data demonstrating the signaling pathways upstream of cytokine release, or indeed 
whether both FFA2 and FFA3 are involved. As with analysis of function of FFA2 and 
FFA3 in other tissues (see later), the low potency and  pleiotropic effects of the SCFAs, 
means that without access to new, well characterized and highly selective synthetic 
ligands, unravelling the specific roles of FFA2 and FFA3 in immune cells and in immune 
cell-mediated disease processes will remain challenging. 
 
Roles in the intestine 
C4 is an important energy source for enterocytes, and SCFAs have a multitude of 
positive effects in the colon, such as helping maintain the intestinal barrier, and 
decreasing the risk of cancer (Canani et al., 2011) (Figure 2). Indeed, model animals on 
total parenteral nutrition fare better when supplemented with SCFAs, showing less 
mucosal atrophy, an improvement that correlates with increased expression of 
proglucagon (Gee et al., 1996; Pratt et al., 1996; Tappenden and McBurney, 1998). 
Studies using fluorescently labelled L-cells show FFA2 to be highly expressed in colonic 
L-cells, and FFA3 in small intestinal L-cells (Tolhurst et al., 2012). FFA3 partially co-
localizes with gastrin and ghrelin in the stomach, completely co-localizes with CCK, GIP 
and secretin in the proximal small intestine and with PYY, NT, and GLP-1 in the distal 
small intestine. A gradient of expression of FFA3 increases distally in D-cells and 
enterochromaffin cells. Conversely, FFA2 is only observed sparsely in a subpopulation of 
enteroendocrine cells of the small intestine, although the lack of fluorescence in the 
model used cannot be taken to be conclusive proof of lack of expression (Nøhr et al., 
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2013). In accordance with the expression profile of FFA2 and FFA3, stimulation of 
enteroendocrine cells with SCFAs can trigger GLP-1 (Reimer and McBurney, 1996; Lin 
et al., 2012; Tolhurst et al., 2012; Nøhr et al., 2013; Psichas et al., 2015), GLP-2 (Akiba 
et al., 2015) PYY (Lin et al., 2012; Psichas et al., 2015) and GIP (Lin et al., 2012) 
release. However, reports as to whether oral SCFA can increase enteroendocrine 
hormones in vivo are mixed. One study found oral SCFAs had no effect on GLP-1, but 
decreased the plasma GIP response to glucose challenge (Tang et al., 2015). FFA2 
agonists may also act on EC cells to trigger 5-HT release, which together with GLP-2 
would help prevent mucosal injury (Akiba et al., 2015), suggesting a mechanism for the 
benefits to adding SCFAs to TPN. Finally, there is a link between SCFAs and decreased 
intestinal motility, which is FFA3 and neuroendocrine independent (Dass et al., 2007). 
Overall, results show that FFA2 and FFA3 are involved in enteroendocrine hormone 
production and intestinal functions, but further studies with selective synthetic ligands 
and new animal models are needed to better define the roles of these receptors in the 
intestine.  
 
Roles in the pancreas 
Early reports showed that C2 improves glucose clearance in rats (Shah et al., 
1977), and improves glucose-stimulated insulin secretion (GSIS) in isolated rat islets 
(Patel and Singh, 1979).  More recently it has been demonstrated that islets express both 
FFA2 and FFA3 (Brown et al., 2003; Leonard et al., 2006; Regard et al., 2007) (Figure 
2), and crucially they are found in beta cells of the islet (Tang et al., 2011). Interestingly, 
FFA2 is upregulated in pregnancy in the mouse, suggesting that it may aid in this insulin-
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resistant state (Layden et al., 2010). This suggests a simple relationship of FFA2/3 
agonism leading to insulin secretion, but the reality is likely to be more complicated. One 
study has reported that while C2 increases insulin secretion via FFA2 (Priyadarshini et 
al., 2015), C3 inhibits insulin secretion via FFA3 (Priyadarshini and Layden, 2015).  
Other results indicate that C2 has an autocrine role, suggesting it to inhibit insulin 
secretion via G±i/o coupled to both FFA2 and FFA3 in beta cells (Tang et al., 2015). The 
latter appears more logical, given the importance of cAMP in boosting GSIS (Yajima et 
al., 1999).  Interpretation must remain cautious at this point, however, because it is 
possible that different SCFAs display ligand bias (see later) at FFA2/3. For example, 
FFA2 agonist-mediated enhancement of GSIS activation is reported to be via PLCβ 
(Priyadarshini et al., 2015). Perhaps FFA2-dependant effects of C2 in the islet are biased 
to G±q over G±i/o. Studies in FFA2 knock-out mice showed a depressed level of plasma 
insulin in response to an oral glucose load, but it is difficult to draw firm conclusions 
from these data given that FFA2 also plays a role in GLP-1 secretion (Tolhurst et al., 
2012) and insulin sensitivity (Bjursell et al., 2011), both of which would be anticipated to 
have a knock-on effect on insulin levels. To describe separate, potentially opposing roles 
of FFA2 and FFA3 in the islet, selective ligands for each receptor are sorely needed.  
 
Roles in adipose tissue 
There is strong evidence for the presence of FFA2 in adipocytes (Figure 2). Two 
of the original de-orphanization studies noted this (Brown et al., 2003; Le Poul et al., 
2003), and subsequent studies have agreed (Ge et al., 2008; Al-Lahham et al., 2010; 
Lemor et al., 2010; Kimura et al., 2013). The presence of FFA3, however, remains a 
subject of debate. FFAR3 mRNA is reported to be in adipose tissue and adipocyte cell 
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lines (Le Poul et al., 2003; Xiong et al., 2004; Mielenz et al., 2008; Al-Lahham et al., 
2010) but, equally, many groups report that adipocytes themselves do not possess the 
receptor (Brown et al., 2003; Hong et al., 2005; Zaibi et al., 2010; Bellahcene et al., 
2013). Knocking out FFA2 expression has not provided clarity as to its possible function 
in adipocytes. FFA2 receptor knock out lines have been reported to show both increase 
adiposity (Kimura et al., 2013), and protect against diet-induced obesity (Bjursell et al., 
2011).  In addition, lean and obese humans have similar expression levels of FFA2 
(Dewulf et al., 2013). Still, it is clear that SCFAs act on adipocytes. C2 derived from 
alcohol metabolism reduces circulating FFAs (Crouse et al., 1968), and resistant starch 
supplementation inhibits lipolysis and hormone-sensitive lipase to the same effect 
(Robertson et al., 2005; Ge et al., 2008). Exogenous C2, C3 and C4 all inhibit lipolysis 
(Hong et al., 2005; Ge et al., 2008; Zaibi et al., 2010).  Importantly this effect is PTX-
sensitive (Ohira et al., 2013), and absent in FFA2 knock-out mice (Ge et al., 2008). 
Reports suggest that FFA2 activation reduces insulin sensitivity in the adipocyte, by G² ³ -
mediated inhibition of Akt phosphorylation downstream of the insulin receptor (Kimura 
et al., 2013). 
SCFA can drive adipocyte differentiation from stem cells (adipogenesis). C2 and 
C3 trigger the pre-adipocyte cell line 3T3-L1 to differentiate, and C3 increases 
expression of the adipogenesis markers PPAR-³ 2 and C/EBP±. When these cells are 
treated with siRNA against FFA2, expression of PPAR-³ 2 and aP2 (another adipocyte 
marker) decrease (Hong et al., 2005). FFA2 knock-out mice have less adipocytes 
(Bjursell et al., 2011) but, curiously, these findings from rodent models may not translate 
to humans. Adipocytes cultured from the omentum did not show any increase in aP2 after 
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treatment with FFA2 agonists (Dewulf et al., 2013). A lack of difference in white adipose 
tissue between FFA2 knock-out and wild type pups in the embryonic stage have even led 
one group to conclude that the effect of FFA2 in adipogenesis may be an in vitro artefact 
(Kimura et al., 2013). 
Finally, the adipocyte does not function as merely an inert energy store; it is also 
an endocrine cell, secreting metabolic hormones including adiponectin and leptin (Sethi 
and Vidal-Puig, 2007).  Higher levels of leptin have been reported in both FFA2 (Bjursell 
et al., 2011) and FFA3 knock-out mice fed a high fat diet (Bellahcene et al., 2013) 
although a different FFA2 knock-out  line had plasma leptin levels comparable to wild 
type (Kimura et al., 2013). In vitro, SCFAs also increase leptin mRNA in bovine 
adipocytes (Soliman et al., 2007) and increase leptin secretion from primary murine 
adipocytes (Xiong et al., 2004), both in a PTX-sensitive manner. As all these somewhat 
contradictory studies demonstrate, the true role of the FFA2 in the adipocyte is far from 
fully defined.  
 
Roles in neurons 
The autonomic nervous system regulates energy output, and in particular the 
sympathetic nervous system acts to decrease energy use during periods of starvation 
(Kimura et al., 2011). It has been proposed that SCFAs can act at FFA3 as a switch to 
modulate sympathetic regulation of energy. In times of plenty, plasma levels of C4 will 
increase (especially if diets are high in fiber) (Nilsson et al., 2010), whereas during 
starvation, levels of ketone bodies such as ² -hydroxybutyrate (BHB) – a putative FFA3 
antagonist (Inoue et al., 2012) (or possibly agonist) (Won et al., 2013) will increase.  
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FFA3 is expressed by both prevertebral and paravertebral ganglia (Kimura et al., 
2011; Won et al., 2013; Nøhr et al., 2015) (Figure 2). FFA3 knock-out mice have a 
lower resting heart rate, and less sympathetic innervation of the heart, whereas C3 given 
to wild type mice can raise heart rate. Co-culturing cardiomyocytes and neurons together 
reveals a FFA3-dependent relationship where C3 can increase beat rate. This effect is 
PTX-sensitive, and involves G² ³ , PLC² , and ERK/12 MAP kinases. In this system, BHB 
can antagonize the effect of C3 (Kimura et al., 2011). C3 causes the release of 
noradrenaline from the superior cervical ganglion via the same signaling cascade and 
synapsin 2. Again, this is inhibited by BHB (Inoue et al., 2012).  However, there is a 
conflicting report that describes a different mechanism of FFA3 action. Won et al., 
(2013) showed inhibition of N-type Ca2+ channels by G² ³  complex generated by 
activation of FFA3, an effect that was elicited by each of C2, C3 and BHB, and would 
presumably decrease catecholamine release from neurons (Won et al., 2013).  How these 
data fit within the sympathetic modulation theory remains to be defined.  
 FFA3 is also expressed in ganglia of the enteric and sensory nervous systems, i.e. 
submucosal ganglia, myenteric ganglia, nodose ganglion, dorsal root ganglia, and 
trigeminal ganglia (Nøhr et al., 2013, 2015). The physiological function of FFA3 in these 
ganglia has yet to be described. Finally, FFA3 co-localizes with a neuronal marker in the 
portal vein wall, where it is proposed that C3 can act to form a gut-brain axis regulating 
intestinal gluconeogenesis (De Vadder et al., 2014).  
 
Experimental challenges and current perspectives for the validation of FFA2/FFA3 as 
therapeutic target(s) 
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Target validation is an essential step in drug-development studies and assists in 
defining the physiological role(s) of a GPCR and its importance in patho-physiological 
conditions, with the aim of developing a pipeline of potential therapeutic medicines 
(Smith, 2003). Among several approaches, validation of a GPCR can be achieved by 
employing ligands that selectively perturb the target of interest in vitro and/or in vivo.  
 
Synthetic ligands for SCFA receptors 
There is a general paucity of selective ligands for FFA2 and FFA3 and the co-expression 
of these two GPCRs in several tissues (see earlier) presents major obstacles in 
understanding the patho-physiological role of each receptor. This is further complicated 
by differences between the pharmacology of species orthologs of FFA2 and FFA3 
(Figure 1). For example, although C2 has been used in a number of in vivo studies both 
because it is the most abundant SCFA in the body (McOrist et al., 2008) and because of 
its reported selectivity for FFA2 over FFA3 (Schmidt et al., 2011), this selectivity of C2 
is most pronounced at the human SCFA receptors. By contrast, (Hudson et al., 2012b) 
demonstrated that this is not the case for the murine orthologs of FFA2 and FFA3 
(Figure 1). Indeed, for the mouse receptors C2 is equipotent in activating FFA2 and 
FFA3. Moreover, no endogenous SCFA is sufficiently selective to define a role for FFA2 
over FFA3, or vice versa, in murine cells and tissues (Hudson et al., 2012b). This 
highlights the need for more potent and markedly more selective ligands for the two 
receptors.  
 
Orthosteric agonist ligands 
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Pleiotropic non-receptor-mediated effects, as well as the low potency and lack of 
selectivity of the SCFAs between FFA2 and FFA3, has certainly become a major obstacle 
to the study of the function of these receptors, both in vitro and in vivo. The work of 
Schmidt et al. (2011) highlighted that although small molecules containing a carboxylic 
acid group can achieve close to optimal LE and a reasonable degree of selectivity at 
FFA2 vs FFA3, their modest potency, and a lack of knowledge of potential ‘off-target’ 
effects, means they remain unsuitable for ex-vivo and/or in vivo study of these receptors, 
although they have been used in a limited number of cases (e.g. (Priyadarshini et al., 
2015)).  
The first class of more potent synthetic ligands of FFA2 were initially described and 
patented by Euroscreen (Hoveyda et al., 2010).  From this series of ligands, Hudson et 
al., (2013b) synthesized and characterized ‘compound 1’ (3-benzyl-4-(cyclopropyl-(4- 
(2,5-dichlorophenyl)thiazol-2-yl)amino)-4-oxobutanoic acid) as a selective orthosteric 
agonist at human FFA2 (Figure 1). In a range of assays, including those reflecting FFA2-  
mediated G±i/o, G±q/11 and ² -arrestin pathways, this ligand is able to activate human 
FFA2 with potency in the high nanomolar range. The mode of binding of this ligand has 
not yet been completely elucidated. ‘Compound 1’ and related molecules contain a 
carboxylic acid pharmacophore, and this is required for function because replacement by 
a methyl or tert-butyl ester eliminates activity (Hudson et al., 2013b). Moreover, it is 
clearly orthosteric in action as it also lacks function at mutants of the key positively 
charged residues of the orthosteric binding site of human FFA2 (Hudson et al., 2013b).  
Moreover, function of ‘compound 1’ is inhibited by the orthosteric antagonist, CATPB 
(Hudson et al., 2013b) in a competitive and surmountable fashion. However, ‘compound 
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1’ contains also the N-thiazolyamide pharmacophore, as found in the allosteric agonist 4-
CMTB. Despite this, ‘compound 1’ does not appear to act as a ‘bitopic’ ligand (Lane et 
al., 2013) because in ² -arrestin-2 recruitment assays ‘compound 1’ did not also display 
competitive interactions with 4-CMTB (Hudson  et al., 2013b). Studies with related 
compounds, designated 9, 14, 101 and 105, containing both carboxylate and N-
thiazolyamide moieties (Brown et al., 2015) indicated these ligands were also able to 
interact with the orthosteric binding site of FFA2, but not with the allosteric binding site. 
In cells endogenously expressing FFA2 ‘compound 1’ has been reported to reduce 
lipolysis in both the human and mouse immortalized adipocyte cell lines, SW872 and 
3T3-L1 respectively, with a mechanism that has been shown to be G±i/o dependent. 
Moreover, ‘compound 1’ has also been reported to induce GLP-1 release from the murine 
STC-1 enteroendocrine cell line (Hudson et al., 2013b). Importantly, although 
‘compound 1’ displays reasonable potency at rodent orthologs of FFA2 (Hudson et al., 
2013b), certain other compounds from this chemical series show markedly lower potency 
at the rodent forms compared to human (Hudson et al., 2013b). Although potentially a 
good deal might be learned from a systematic SAR analysis of this compound series, 
such studies have not been reported to date. Docking studies of ‘compound 1’ to a 
homology model of human FFA2 revealed that the phenyl substituent in this ligand may 
interact with residue position 3.29 of the receptor (Hudson et al., 2013b). Interestingly, 
this residue differs between human (serine) and rodent (glycine) orthologs. More 
recently, a further homology model of this receptor, based on the x-ray structure of the 
related receptor FFA1, has indicated that tyrosine 90 (residue position 3.33) is also in 
close proximity to this phenyl ring (Sergeev et al., 2016) and mutation of this residue has 
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also previously been shown to markedly reduce the potency of ‘compound 1’ (Hudson et 
al., 2013b). 
 
Orthosteric antagonist ligands 
Receptor antagonists, by blocking the action of either endogenous or synthetic 
agonists, routinely provide powerful tools to help define biological roles of a receptor. 
Interest in the biological actions and potential therapeutic application of FFA2 
antagonists emerged with the discovery that FFA2 is expressed by neutrophils and can 
dictate their migration in inflammatory states, including those of the lower intestine 
(Maslowski et al., 2009; Sina et al., 2009). Moreover, recent studies have showed that 
FFA2 and FFA3 activation in beta cells of the pancreas can block insulin secretion (Tang 
et al., 2015), suggesting that antagonists at either (or both) of these receptors could be 
beneficial for the treatment of type II diabetes.  
In recent years, two series of FFA2 antagonists have been described. The first 
series of antagonists was reported by Euroscreen (Brantis et al., 2011).  Among those 
compounds, (S)-3-(2-(3-chlorophenyl)acetamido)-4-(4-(trifluoromethyl)phenyl)butanoic 
acid (CATPB) (Figure 1) inhibited effects of C3 in cells expressing human FFA2 in both 
[35S]GTPγS  binding and calcium-based assays, with reported pIC50 of  7.70 and 8.00, 
respectively (Brantis et al., 2011).  Lack of effect in cells expressing FFA3 indicated 
CATPB to be specific for FFA2. Experiments using [3H]CATPB showed that C3 was 
able to fully displace the radiolabeled ligand, consistent with, although not defining, that 
CATPB binds to the orthosteric site of human FFA2 (Brantis et al., 2011).  Subsequent 
experiments employing [35S]GTPγS binding revealed that CATPB was also able to 
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decrease the constitutive activity of human FFA2 expressed in HEK293 cells, indicating 
that CATPB acts as an inverse agonist at this receptor (Hudson et al., 2012b).  
The second series of FFA2 receptor antagonists contains an azetidine 
pharmacophore and was reported by Galapagos NV as potentially of interest for their 
effects in metabolic and inflammatory disorders, based on an ability to block SCFA-
induced neutrophil migration (Sanière et al., 2012). The most studied compound from 
this series is 4-[[(R)-1-(benzo[b]thiophene-3-carbonyl)-2-methyl-azetidine-2-carbonyl]-
(3-chloro-benzyl)-amino]-butyric acid (GLPG0974) (Figure 1). This ligand showed high 
potency to antagonize acetate-mediated Ca2+-elevation, with a reported pIC50 of 8.04 
(Pizzonero et al., 2014).  Using human neutrophils this compound blocked both acetate-
induced migration and expression of the neutrophil activation marker, CD11b[AE], 
consistent with a potential capacity of GLPG0974 to decrease inflammatory processes 
(Pizzonero et al., 2014). Good pharmacodynamic properties and the pharmacokinetic 
profile of this ligand resulted in ‘first in man’ trials of GLPG0974 in a phase 2, 
randomized, double blind, and placebo-controlled clinical trial in 2013. During this study, 
the safety and efficacy of the compound were tested in patients affected by mild to 
moderate ulcerative colitis. However, no improvement in the clinical profile of patients 
over a short-term treatment resulted in termination of this programme.  
FFA2 antagonists could represent an extremely useful tool for pre-clinical drug 
development and proof of concept studies. Unfortunately neither of the FFA2 antagonists 
that have been described to date in primary peer-reviewed publications (CATPB and 
GLPG0974) appear able to interact with rodent orthologs of FFA2 (Figure 1). Recently, 
Sergeev and colleagues analyzed the binding interaction of [3H]GLPG0974 at hFFA2. 
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From this study it emerged that the orthosteric antagonists, GLPG0974 and CATPB, do 
not require interaction with both Arginine residues, Arg 5.39 and 7.35, in the orthosteric 
binding pocket in order to engage with the receptor (Sergeev et al., 2016). In addition, it 
was found that these different classes of antagonists displayed preferential interaction 
with different arginine residues (Sergeev et al., 2016). The characterization of ligand-
receptor interactions is likely to be important for the design of ligands that also display 
antagonism at rodent orthologs of the receptor. 
 
Allosteric ligands 
Allosteric modulators are defined as ligands that interact at a site of a receptor 
which is distinct from and does not overlap with the orthosteric binding site. The 
interaction of a ligand with an allosteric binding site can generate a conformational 
change in the receptor that is transduced to the orthosteric site and/or directly to the 
intracellular effector (Kenakin and Miller, 2010; Wootten et al., 2013). Allosteric ligands 
can regulate the affinity and/or the potency of orthosteric ligands in a positive (positive 
allosteric modulators, PAMs) or negative (negative allosteric modulators, NAMs) manner 
(Kenakin and Miller, 2010; Wootten et al., 2013. Molecules may also bind to the 
allosteric site but have no effect on receptor activity in which case they are called neutral 
allosteric ligands (NALs). In addition to potentially modulating the activity of orthosteric 
ligands allosteric modulators may also possess agonist activity, or intrinsic activity, in 
their own right (Kenakin and Miller, 2010; Wootten et al., 2013). This is often only 
evident at high levels of occupancy of the allosteric site and in highly sensitive signal 
transduction assays.  
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Therapeutically, allosteric ligands potentially offer certain advantages over 
orthosteric ligands. This includes improved selectivity due to the fact that allosteric sites 
are often in non-conserved regions of the receptor and that the co-operativity of allosteric 
ligands can be receptor subtype specific. Furthermore, the effects of allosteric modulators 
are saturable, and this can limit possible side-effects including overdose. Moreover, 
PAMs and NAMs have the advantage of maintaining both temporal and spatial properties 
of endogenous ligand function, without altering or disrupting the physiological system 
(Kenakin and Miller, 2010; Wootten et al., 2013).  
Currently phenylacetamides, of which 4-CMTB (Figure 1) is by far the most 
studied example, represent the only described class of allosteric modulators at FFA2.  4-
CMTB is an allosteric agonist at FFA2 in that it has the ability to activate G±i/o, G±q/11 
and ² -arrestin-mediated FFA2 pathways directly as well as behaving as a PAM of the 
potency of SCFAs (Lee et al., 2008; Wang et al., 2010; Smith et al., 2011). However, 
some studies suggest that 4-CMTB might affect various FFA2-mediated signaling 
responses somewhat differently than SCFAs (Smith et al., 2011). Whether 4-CMTB 
displays ‘functional selectivity’ (Hudson et al., 2013a) at FFA2 thus deserves further 
investigation. 
In vitro, 4-CMTB has been found to produce inhibition of lipolysis in both mouse 
and human adipocytes (Lee et al., 2008; Wang et al., 2010; Brown et al., 2015),  to 
induce GLP-1 release from enteroendocrine cells (Brown et al., 2015) and to promote 
chemotaxis of neutrophils (Vinolo et al., 2011).  Unfortunately, 4-CMTB has poor 
pharmacokinetic properties (Wang et al., 2010) and consequently it is not suitable for in 
vivo validation of FFA2. 
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There is an even greater paucity of available FFA3-selective ligands. The only 
currently described class of synthetic ligands was identified by Arena Pharmaceuticals 
(Leonard et al., 2006). This series of ligands was later shown to contain each of allosteric 
agonists, PAMs, NAMs and PAM-antagonists (Hudson et al., 2014), although the basis 
for the SAR of such effects remains uncharted. One compound derived from this series, 
AR420626 (Figure 1), has been used to demonstrate the involvement of SCFAs in both 
GLP-1 secretion from colonic crypts (Nøhr et al., 2013) and ghrelin secretion from 
gastric mucosa cells (Engelstoft et al., 2013).  Although this class of compounds needs to 
be further developed and characterized, the diverse and rather complex pharmacology of 
this series of ligands could provide new insight into the biological functions of FFA3. 
Interestingly, FFA2 and FFA3 allosteric modulators show similar function at human and 
rodent orthologs of those receptors, where they retain both their potency and allosteric 
properties (Lee et al., 2008; Hudson et al., 2012b and 2014). This is in contrast to the 
behavior of the synthetic orthosteric ligands discussed above. Although it has been 
reasoned that allosteric binding sites should be under less evolutionary pressure to be 
maintained than orthosteric sites because endogenously produced regulators to not bind 
to these regions (May et al., 2007, Hudson et al., 2013a) it has been helpful that the 
allosteric ligands described above do display function at rodent orthologues of FFA2 and 
FFA3.  Considering that different species ingest different amounts of fiber and they are 
consequently exposed to varying concentrations of SCFAs (Dranse et al., 2013; Milligan 
et al., 2014), it is reasonable to imagine that this may have driven alterations in the 
orthosteric binding site between species (Hudson et al., 2014). This could be extremely 
important in terms of drug development programs. As already introduced, as well as 
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showing activity at the human receptor, ligands preferably should show activity in 
different species as pre-clinical studies are performed in animal models. In this regard, 
allosteric modulators at FFA2 could be useful approach to validate FFA2/FFA3 in vitro 
and in vivo.  
 
Biased ligands 
In the last 20 years it has become clear that some ligands have the ability to preferentially 
activate specific receptor-mediated intracellular signaling pathways over others. This 
phenomenon is defined as “biased signaling” or “functional selectivity” and is believed to 
reflect the capacity of a receptor to adopt multiple activated states and/or the ability of a 
ligand to preferentially induce specific receptor active states (Kenakin, 2013; Kenakin 
and Christopoulos, 2013). It has been suggested that such ‘biased’ ligands may have 
clinical benefit if they can facilitate beneficial physiological processes without 
simultaneously driving signals that may be contra-indicated.  This has generated many 
ideas in ligand design and, although still to be shown directly to result in clinical benefit, 
highlights the need to pharmacologically characterize ligands in an array of functional 
assays (Kenakin and Christopoulos, 2013; Kenakin, 2015). FFA2 in particular has been 
reported to be a promiscuous receptor due to its ability to interact with various G proteins 
and also to recruit arrestins (Brown et al., 2003; Stoddart et al., 2008b). Signal bias is 
certainly not restricted to synthetic ligands. For example, endogenous ligands for 
chemokine receptors clearly exert bias (Zweemer et al., 2014) and for receptors, such as  
FFA2, that respond to multiple endogenously generated ligands, there may be potential 
for these to display variation in signal flux.  
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At present it is unclear whether different SCFAs display bias or indeed, whether 
such bias at SCFA receptors could have a therapeutic application. Certainly, however, 
biased agonists at FFA2 or FFA3 would be invaluable tools to understand the 
physiological implications of distinct signaling pathways to the biological effect of these 
receptors. For example, the role of FFA2 in pancreatic beta cells remains controversial 
(Priyadarshini et al., 2015; Tang et al., 2015). Nonetheless, G±q/11 and G±i/o-dependent 
pathways in beta cells seem to exert opposite effects relative to insulin secretion, with 
activation of G±q/11 signaling leading to increased levels of this hormone, and of G±i/o to 
diminished secretion (Winzell and Ahrén, 2007; Priyadarshini et al., 2015). Whether 
FFA2 activation in human pancreatic islets can signal through both G±q/11 and G±i/o 
pathways is still unclear. However, a biased agonist at FFA2 that would preferentially 
function through G±q/11, rather than G±i/o would certainly be a valuable pharmacological 
tool to unravel the relative importance of FFA2 signaling pathway/s and their biological 
role in pancreatic beta cells and potentially in type 2 diabetes. 
 
Limits and extensions to FFA2 and FF3 knock-out studies 
 As highlighted earlier, a useful technique for discovering the function of GPCRs 
is to create transgenic mouse knock-out models, and characterize the resulting 
phenotype(s). In the case of FFA2 and FFA3 however, the results of knocking out either 
receptor have proven to be conflicting. For example, a disparity is seen in adiposity 
between the different knock-out models. The FFA2 knock-out mouse produced by 
Kimura et al. is heavier than the wildtype, and has more adipose tissue (Kimura et al., 
2013), but another model shows no difference in weight gain between wildtype and 
knock-out (Tang et al., 2015), while yet another actually shows the knock-out is 
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protective against weight gain on a high fat diet (Priyadarshini et al., 2015).  Likewise 
FFA3 knock-out models have both increased adiposity (Bellahcene et al., 2013), and the 
same amount of adipose tissue as wildtype (Samuel et al., 2008). Model-dependent 
differences have also been observed in glucose tolerance and insulin sensitivity in both 
FFA2 (Bjursell et al., 2011; Tolhurst et al., 2012; Priyadarshini et al., 2015; Tang et al., 
2015) and FFA3 knock-out lines (Kimura et al., 2011; Tolhurst et al., 2012; Tang et al., 
2015). 
These discrepancies may be for one of two reasons. Firstly, as the endogenous 
ligands for FFA2 for FFA3 overlap between the two receptors, knock-out of one may 
simply result in the compensation by the other. Secondly, FFAR2 and FFAR3 in mouse 
are located adjacent to each other on chromosome 7. Attempts to alter the transcript for 
one gene may affect the transcription of the other. One group has indeed reported that 
FFA2 was down-regulated in their FFA3 knock-out model (Zaibi et al., 2010), while 
others have not checked for this issue.  
 
Chemogenetic approaches to determining the physiological function and drug 
responses of FFA2 and FFA3  
Whereas gene knock-out studies provide an approach for understanding the 
physiological role of FFA2 and FFA3 and provide important indications of the 
physiological impact and clinical potential of targeting these receptors, there are more 
sophisticated genetic approaches that can be adopted that can provide a direct measure of 
the impact of pharmacologically selective ligands. Work centered largely on the 
muscarinic receptor family has provided the framework for the development of a 
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chemogenetic approach where mutations introduced into the orthosteric binding site of 
receptors result in a loss of activity to the natural ligand but, instead, allows the receptor 
to be activated by a synthetic chemical ligand that is otherwise inert (Armbruster et al., 
2007; Dong et al., 2010; Alvarez-Curto et al., 2011; Urban and Roth, 2015). Such 
receptor mutants have been termed Designer Receptors Exclusively Activated by 
Designer Drugs (DREADDs) and have been used extensively to define G protein 
dependent in vivo responses (Urban and Roth, 2015).  
Using the distinct endogenous ligand selectivity of bovine and human FFA2, two 
mutations introduced into the orthosteric binding site of human FFA2 reduced the 
response of the receptor to endogenous SCFAs by >100 fold.  This receptor mutant was 
instead activated by sorbic acid, a naturally produced but not endogenously generated 
ligand, that activates bovine FFA2 but not human FFA2, as well as a series of small 
synthetic compounds  (Hudson et al., 2012a) (Figure 3). Hence these studies generated 
the first genuine FFA2-DREADD receptor which possessed the following properties (i) 
the FFA2-DREADD was no longer activated by endogenous SCFAs, (ii) instead this 
receptor mutant was activated by a synthetic chemical ligand (e.g. in this case sorbic 
acid) and (iii) the wild type receptor (i.e. human FFA2) was not activated by the synthetic 
ligand (Hudson et al., 2012a) (Figure 3). 
This FFA2-DREADD opens up the possibility of employing a chemogenetic 
approach akin to that successfully employed by the muscarinic-DREADDs. Hence, by 
using gene targeting techniques that replace the mouse FFA2 gene with the coding 
sequence for the FFA2-DREADD then the mutant receptor will be expressed at 
physiologically relevant levels and in the same cell types as the wild type FFA2. By 
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administration of sorbic acid to these FFA2-DREADD mutant mice researchers will not 
only be able to define the physiological role of FFA2 but also this approach will provide 
the first insights into the potential therapeutic response that can be expected of a drug that 
selectively targets FFA2 (Figure 3). Moreover, the FFA2-DREADD retains high affinity 
for the human specific antagonist ligands CATPB and GLPG0974. As such, on target, 
FFA2-DREADD mediated effects of sorbic acid will block such effects but not potential 
off target effects (Figure 3). It will be fascinating to see the results of such studies, not 
least as FFA3 will still be responsive to the endogenously generated SCFAs.   
Conclusions 
SCFA receptors are relatively newly discovered GPCRs. Emerging evidence suggests 
that these receptors are implicated in a variety of physiological functions and their 
pharmacological modulation could represent invaluable therapeutic targets. However, 
translational pharmacology has been limited by a paucity of selective ligands and by 
receptor species ortholog differences. Moreover, animal genetic knock-out approaches 
have resulted in challenging data interpretation, due perhaps to compensatory effects. 
Alternative and more refined strategies, such as the DREADD chemogenetic approach 
may hold great potential to unravel the impact of pharmacologically selective ligands at 
FFA2, and also define the physiological importance of FFA2 vs FFA3.     
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Legends for Figures 
Figure 1 
Selectivity of ligands at human and murine FFA2 and FFA3. The main endogenous 
SCFAs (C2, C3 and C4) activate FFA2 and FFA3 with varying potency (denoted by the 
thickness of the arrow) and the rank order of activity is not maintained between human 
and mouse species orthologs (Hudson et al., 2012b). Synthetic allosteric agonists at 
FFA2 are represented by phenylacetamides, where 4-CMTB is the most potent ligand 
(Lee et al., 2008; Wang et al., 2010; Smith et al., 2011) and it maintains its activity 
across human and mouse FFA2 (Hudson et al., 2012b). Allosteric modulators at FFA3 
are represented by a class of synthetic ligands that comprises allosteric agonists, such as 
AR420626, and allosteric antagonists, such as ‘compound 6’ (Hudson et al., 2014). Both 
AR420626 and ‘compound 6’ maintain their activity at the murine species ortholog (Nøhr 
et al., 2013; Engelstoft et al., 2013; Hudson et al., 2014). Synthetic orthosteric agonists at 
FFA2 are represented by ‘Compound 1’ (Hudson et al., 2013b) and SCAs with sp and sp2 
hybridized ± carbon (Schimdt et al., 2011). Alternative, SCAs with substituted sp3 
hybridized ± carbon have a degree of selectivity for FFA3 (Schimdt et al., 2011). The 
degree of selectivity of ‘compound 1’ and SCAs is relatively well maintained between 
human and mouse species orthologs (Hudson et al., 2012b and 2013b). Synthetic 
orthosteric antagonists at FFA2 are represented by GLPG0974 and CATPB, however 
these compounds show affinity only for the human species ortholog (Hudson et al., 
2012b; Sergeev et al., 2015).  
 
Figure 2 
Key actions of SCFAs at sites which express FFA2 and/or FFA3. The physiological roles 
of FFA2 and FFA3 are complex, and yet to be completely elucidated. Details that remain 
contentious are marked with a ‘?’. In PMNs/PBMCs FFA2 causes chemotaxis down a 
SCFA gradient, and elicits changes in ROS signaling and cytokine release (Säemann et 
al., 2000; Cavaglieri et al., 2003; Sina et al., 2009; Vinolo et al., 2009, 2011). In 
enteroendocine cells, FFA2 and FFA3 cause secretion of a variety of gut hormones (Lin  
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et al., 2012; Tolhurst et al., 2012; Akiba et al., 2015; Psichas et al., 2015). FFA2 
promotes adipogenesis, decreases lipolysis, and possibly increases leptin secretion from 
adipocytes (Xiong et al., 2004; Hong et al., 2005; Ge et al., 2008; Zaibi et al., 2010). 
FFA3 in neurons increases sympathetic innervation and increases plasticity in the enteric 
nervous system (Soret et al., 2010; Kimura et al., 2011). In the pancreas acetate may 
increase and propionate decrease insulin secretion (Priyadarshini and Layden, 2015; 
Priyadarshini et al., 2015).  
 
Figure 3 
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) strategy for 
FFA2. In wild type-animals, FFA2 and FFA3 are both activated by SCFAs, i.e. 
propionate (C3). In tissues co-expressing both SCFA receptors, the physiological 
response of C3 results from the activation of both FFA2 and FFA3. In mice engineered 
with the humanized FFA2-DREADD, the mutated FFA2 is solely activated by the 
administration of the non-endogenous ligand, sorbic acid, and inert to the endogenous 
ligand, C3. Hence, the physiological responses of C3 results only from FFA3 activation, 
while the responses of sorbic acid is uniquely mediated by FFA2-DREADD activation. 
Moreover, the FFA2-DREADD retains high affinity for the human specific antagonist 
ligands CATPB and GLPG0974. As such, on-target FFA2-DREADD-mediated responses 
of sorbic acid will be blocked by these antagonists but not potential off-target effects. 
 
